<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab †</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-05-13">13 May 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">German Breast Group</orgName>
								<address>
									<settlement>Neu-Isenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Centre Hospitalier Universitaire de Besançon</orgName>
								<address>
									<addrLine>Service d&apos;Oncologie Médicale</addrLine>
									<settlement>Besançon cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Majewski</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">The Netherlands Cancer Institute</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">National Centre for Tumour Diseases</orgName>
								<address>
									<settlement>Heidelberg</settlement>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Guarneri</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Surgery, Oncology and Gastroenterology</orgName>
								<orgName type="institution" key="instit1">University of Padua</orgName>
								<orgName type="institution" key="instit2">Veneto Institute of Oncology IOV-IRCCS</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">3rd Medical Department-Centre for Oncology and Haematology</orgName>
								<orgName type="laboratory">Abt.-Zentrum für Onkologie und Hämatologie</orgName>
								<orgName type="institution" key="instit1">Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology</orgName>
								<orgName type="institution" key="instit2">Kaiser Franz Josef-Spital</orgName>
								<address>
									<addrLine>4 3. Med</addrLine>
									<settlement>Vienna</settlement>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution" key="instit1">Ludwig Boltzmann Institut für angewandte Krebsforschung (LBI-ACR VIEnna)</orgName>
								<orgName type="institution" key="instit2">Kaiser Franz Josef-Spital</orgName>
								<address>
									<settlement>Wien</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Nekljudova</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">German Breast Group</orgName>
								<address>
									<settlement>Neu-Isenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Centre Hospitalier Universitaire de Besançon</orgName>
								<address>
									<addrLine>Service d&apos;Oncologie Médicale</addrLine>
									<settlement>Besançon cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Holmes</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Frontier Science Scotland</orgName>
								<address>
									<settlement>Kincraig</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Bria</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Departments of Biostatistics</orgName>
								<orgName type="institution">Eisai Inc</orgName>
								<address>
									<addrLine>Oncology PCU; 6 Oncology</addrLine>
									<settlement>Woodcliff Lake</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Denkert</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Charité Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Schem</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University Hospital Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="laboratory">Centre Hospitalier Universitaire Vaudois (CHUV)</orgName>
								<address>
									<settlement>Lausanne</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Sotiriou</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Institut Jules Bordet</orgName>
								<orgName type="institution">Université Libre de Bruxelles</orgName>
								<address>
									<settlement>Brussel</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Loi</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Peter MacCallum Cancer Centre</orgName>
								<address>
									<settlement>East Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Untch</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<address>
									<addrLine>Helios-Klinikum</addrLine>
									<settlement>Berlin-Buch</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Conte</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Surgery, Oncology and Gastroenterology</orgName>
								<orgName type="institution" key="instit1">University of Padua</orgName>
								<orgName type="institution" key="instit2">Veneto Institute of Oncology IOV-IRCCS</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">3rd Medical Department-Centre for Oncology and Haematology</orgName>
								<orgName type="laboratory">Abt.-Zentrum für Onkologie und Hämatologie</orgName>
								<orgName type="institution" key="instit1">Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology</orgName>
								<orgName type="institution" key="instit2">Kaiser Franz Josef-Spital</orgName>
								<address>
									<addrLine>4 3. Med</addrLine>
									<settlement>Vienna</settlement>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution" key="instit1">Ludwig Boltzmann Institut für angewandte Krebsforschung (LBI-ACR VIEnna)</orgName>
								<orgName type="institution" key="instit2">Kaiser Franz Josef-Spital</orgName>
								<address>
									<settlement>Wien</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Bernards</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">The Netherlands Cancer Institute</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">National Centre for Tumour Diseases</orgName>
								<address>
									<settlement>Heidelberg</settlement>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Piccart</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Institut Jules Bordet</orgName>
								<orgName type="institution">Université Libre de Bruxelles</orgName>
								<address>
									<settlement>Brussel</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">German Breast Group</orgName>
								<address>
									<settlement>Neu-Isenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Centre Hospitalier Universitaire de Besançon</orgName>
								<address>
									<addrLine>Service d&apos;Oncologie Médicale</addrLine>
									<settlement>Besançon cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">J</forename><surname>Baselga</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Memorial Sloan-Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="first">German</forename><forename type="middle">Sibylle</forename><surname>Loibl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">X</forename><surname>Pivot</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">German Breast Group</orgName>
								<address>
									<settlement>Neu-Isenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Centre Hospitalier Universitaire de Besançon</orgName>
								<address>
									<addrLine>Service d&apos;Oncologie Médicale</addrLine>
									<settlement>Besançon cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Marmé</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">The Netherlands Cancer Institute</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">National Centre for Tumour Diseases</orgName>
								<address>
									<settlement>Heidelberg</settlement>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Koenigsberg</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Surgery, Oncology and Gastroenterology</orgName>
								<orgName type="institution" key="instit1">University of Padua</orgName>
								<orgName type="institution" key="instit2">Veneto Institute of Oncology IOV-IRCCS</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Frontier Science Scotland</orgName>
								<address>
									<settlement>Kincraig</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">3rd Medical Department-Centre for Oncology and Haematology</orgName>
								<orgName type="laboratory">Abt.-Zentrum für Onkologie und Hämatologie</orgName>
								<orgName type="institution" key="instit1">Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology</orgName>
								<orgName type="institution" key="instit2">Kaiser Franz Josef-Spital</orgName>
								<address>
									<addrLine>4 3. Med</addrLine>
									<settlement>Vienna</settlement>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution" key="instit1">Ludwig Boltzmann Institut für angewandte Krebsforschung (LBI-ACR VIEnna)</orgName>
								<orgName type="institution" key="instit2">Kaiser Franz Josef-Spital</orgName>
								<address>
									<settlement>Wien</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Guo</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Departments of Biostatistics</orgName>
								<orgName type="institution">Eisai Inc</orgName>
								<address>
									<addrLine>Oncology PCU; 6 Oncology</addrLine>
									<settlement>Woodcliff Lake</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Berrak</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Charité Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Wolfer</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University Hospital Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="laboratory">Centre Hospitalier Universitaire Vaudois (CHUV)</orgName>
								<address>
									<settlement>Lausanne</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Xavier</forename><surname>Pivot</surname></persName>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="laboratory">Breast Group</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="institution">GBG Forschungs GmbH</orgName>
								<address>
									<addrLine>Martin-Behaim-Str. 12</addrLine>
									<postCode>63263</postCode>
									<settlement>Neu-Isenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Centre Hospitalier Universitaire de Besançon</orgName>
								<address>
									<addrLine>Service d&apos;Oncologie Médicale, 3 bd Alexander Fleming</addrLine>
									<postCode>25030</postCode>
									<settlement>Besançon cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab †</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-05-13">13 May 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">1A21E66734D559C16AC9EA492C774BB7</idno>
					<idno type="DOI">10.1158/1078-0432.CCR-13-0360</idno>
					<note type="submission">Received 21 April 2016; revised 2 May 2016; accepted 4 May 2016 Received 4 December 2015; revised 2 May 2016; accepted 9 May 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:42+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>PIK3CA</term>
					<term>HER2+ breast cancer</term>
					<term>double anti-HER2 treatment</term>
					<term>pathological complete response</term>
					<term>neoadjuvant</term>
					<term>survival metastatic breast cancer</term>
					<term>triple-negative breast cancer</term>
					<term>eribulin</term>
					<term>clinical trial</term>
					<term>survival</term>
					<term>pooled analysis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>9. Calura E, Martini P, Sales G et al.</s><s>Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>introduction</head><p><s>In HER2-positive (HER2+) primary breast cancer (BC), pathological complete response ( pCR) using neoadjuvant therapy continuously increased by different strategies: addition of trastuzumab to chemotherapy, increased duration of chemotherapy or double anti-HER2 therapy <ref type="bibr" target="#b0">[1]</ref>.</s><s>In studies using up to 24 weeks of an anthracycline-and taxane-based chemotherapy and using a double blockade, the pCR rate increased to more than 60%, approaching 75% in HER2+/hormone-receptor negative (HR−) breast cancer <ref type="bibr" target="#b1">[2]</ref>.</s><s>The only predictive marker for anti-HER2 treatment remains HER2, but resistance markers are lacking.</s><s>One mechanism of interest for HER2 is the Phosphatidylinositol 3kinase (PIK3) pathway.</s><s>PIK3CA and its counterpart Phosphatase and tensine homologue (PTEN) have long been investigated.</s><s>While PTEN status is difficult to be measured, mutations of the PIK3CA are common in BC and can reliably be assessed by different methods <ref type="bibr" target="#b2">[3]</ref>.</s><s>These mutations are predominantly found in hotspots located in the helical and kinase domains (exons 9 and 20), resulting in activation of the kinase.</s><s>It could recently be demonstrated that PIK3CA mutations predict lower pCR to double blockade with trastuzumab and lapatinib as well as trastuzumab plus afatinib in HER2+ primary BC <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>.</s></p><p><s>Despite the fact that data on PIK3CA mutations demonstrate significantly lower pCR rates, this has not led to an inclusion of the marker into routine diagnostics.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>end points</head><p><s>The primary aim of this study was to investigate the association of pCR and PIK3CA mutations in primary HER2+ BC treated with one or two HER2 targeting agents.</s></p><p><s>Secondary aims were to determine the association of pCR and PIK3CA mutations using different pCR definitions, different subgroups defined by exon (exon 9 versus exon 20), HR status (HR+ versus HR−) and anti-HER2 treatment (trastuzumab versus lapatinib versus trastuzumab plus lapatinib) and to test how these factors influenced disease-free survival (DFS) and overall survival (OS) overall.</s><s>pCR was defined as no invasive and no non-invasive residuals in breast and lymph nodes (ypT0 ypN0).</s><s>Patients with missing pCR assessment or information were regarded as no pCR.</s></p><p><s>DFS was defined as time in months from randomization to (local or distant) disease recurrence, secondary malignancy or death due to any cause.</s><s>OS was defined as time in months from randomization to death due to any cause.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>patients and treatment</head><p><s>PIK3CA mutation was assessed in pre-treatment tumour samples from patients enrolled in five prospectively randomized neoadjuvant trials investigating the dual blockade with T/L (supplementary Figure <ref type="figure">S1</ref>, available at Annals of Oncology online).</s><s>In addition to taxane-based chemotherapy, patients received either trastuzumab, lapatinib or the combination of trastuzumab and lapatinib.</s><s>Detailed information on the design and eligibility criteria of the included studies can be accessed elsewhere (GeparQuattro <ref type="bibr" target="#b7">[8]</ref>, GeparQuinto <ref type="bibr" target="#b8">[9]</ref>, GeparSixto <ref type="bibr" target="#b9">[10]</ref>, NeoALTTO <ref type="bibr" target="#b10">[11]</ref>, CHERLOB <ref type="bibr" target="#b11">[12]</ref>).</s></p><p><s>For GeparQuattro and GeparQuinto, the central HER2 status (IHC3+ or ISH ratio &gt;2.2) was determined retrospectively, and only centrally HER2positive tumours were included in the PIK3CA mutation analysis.</s><s>In GeparSixto, HER2 status was assessed centrally before randomization.</s><s>In the NeoALTTO study, HER2 was assessed centrally or locally (after central laboratory accreditation) and for the CHERLOB study, central HER2 testing was available.</s></p><p><s>In the GeparSixto study, PIK3CA mutations were assessed prospectively during the recruitment phase of the study in all patients.</s><s>For all other studies, PIK3CA mutations were assessed retrospectively using formalin-fixed, paraffin-embedded (FFPE) core biopsies that had been prospectively collected.</s></p><p><s>In the CHERLOB study, in 10 patients, PIK3CA was assessed on the surgical tissue.</s></p><p><s>All patients provided their written informed consent for study participation, biomaterial collection and use of biomaterial in research projects.</s><s>The relevant authorities and ethics committees approved the studies.</s><s>The REMARK (Reporting Recommendations for Tumour Marker Prognostic Studies) criteria were followed <ref type="bibr" target="#b12">[13]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PIK3CA mutation assessment</head><p><s>PIK3CA mutations were evaluated in FFPE or fresh-frozen tumour material with a tumour content of ≥20% for the Geparstudies, ≥10% for the</s></p><formula xml:id="formula_0"> | Loibl et al. Volume 27 | No. 8 | August 2016</formula><p><s>original articles</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Annals of Oncology</head><p><s>NeoALTTO and ≥50% for the CHERLOB samples.</s><s>PIK3CA was genotyped using Sanger sequencing (Geparstudies), Sequenom mass-spectrometry genotyping (NeoALTTO) or pyrosequencing (CHERLOB).</s><s>Detailed method descriptions can be found elsewhere <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b13">14]</ref>.</s><s>Various methods were used to determine PIK3CA mutation status.</s><s>In 504 samples, Sanger sequencing evaluated hotspot mutations in exon 9, encoding the helical domain of PIK3CA (E542K, E545K, E547K, A533V, A533T) and in 20, encoding the catalytic domain (H1047R, H1047L, G1007S) <ref type="bibr" target="#b14">[15]</ref>.</s><s>In NeoALTTO (n = 355), the Sequenom mass-spectrometry genotyping system was used to test for hotspot mutations E542A/K, E545A/K and H1047R/L for PIK3CA <ref type="bibr" target="#b5">[6]</ref>.</s><s>In 108 samples, pyrosequencing was used.</s><s>The approach permitted the identification of mutations in codons 542, 545 and 546 of exon 9 (E542K, E545K, E545A, E545G, Q546E, Q546K) and codons 1043, 1047 and 1049 of exon 20 (M1043I, H1047Y, H1047R, H1047L, G1049R, G1049S) of the PIK3CA gene <ref type="bibr" target="#b6">[7]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>statistical analysis</head><p><s>Associations between mutation status (wild-type versus mutant), clinicopathologic characteristics and pCR were investigated with a (continuity corrected) χ 2 tests for categorical variables.</s><s>Univariate analysis using a binary logistic regression model was carried out to estimate the magnitude of the effect.</s><s>Odds ratios (ORs) and 95% confidence intervals (CIs) with a two-sided Wald P value are given.</s><s>A multivariable Cox regression model was fit to adjust for known baseline characteristics (age, tumour stage, nodal stage, histological type, grading, HR status, treatment and study).</s><s>A Breslow day interaction test was carried out for certain (binary) subgroup analyses; an interaction term in logistic regression was used to test for interaction of subgroup factors with more than two categories.</s><s>Survival analyses were carried out using the Kaplan-Meier product-limit method and the Cox proportional hazards regression models to test the prognostic value of PIK3CA mutation status [hazard ratios (HRs) and 95% CIs] for DFS and OS.</s><s>An interaction term in the Cox proportional hazard model was used to test for interaction for time-to-event end points.</s><s>All P values are two-sided, with a P value of ≤5% considered to be statistically significant.</s><s>No adjustment for multiple testing was carried out.</s><s>Statistical analysis was conducted using SAS version 9.2 under SAS Enterprise Guide 4.3 (SAS Institute Inc., Cary, NC).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>results baseline characteristics and mutation frequencies</head><p><s>In the overall study cohort (N = 967), the PIK3CA mutation rate was 21.7%, 21.4% in the GeparStudies, 22.5% in NeoALTTO and 20.4% in the CHERLOB study (supplementary Table <ref type="table">S1</ref>, available at Annals of Oncology online).</s><s>Overall, the mutations in exon 20 were twice as high as in exon 9 (14.5% versus 7.2%).</s><s>Similar rates were seen in the different studies (Geparstudies 13.1% versus 8.3%, NeoALTTO 16.3% versus 6.2%, CHERLOB 14.8% versus 5.6%).</s><s>There was no difference in the PIK3CA mutation rate by HR status (supplementary Table <ref type="table">S2</ref>, available at Annals of Oncology online).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>correlation of mutation and pCR</head><p><s>Overall, pCR rates were significantly lower in the PIK3CA mutant cohort (16.2%), compared with one in the wild-type cohort [29.6% (OR 0.460; 95% CI 0.308-0.685],</s><s>P &lt; 0.001].</s><s>This difference was mainly confined to the HR+ subgroup, with a significant interaction between PIK3CA and HR status (Figure <ref type="figure">1</ref> and supplementary Table <ref type="table">S3</ref>, available at Annals of Oncology online).</s><s>A significantly different pCR rate between PIK3CA mutant and wild-type tumours could only be observed in the group receiving trastuzumab and lapatinib [16.7% versus 39.1%; OR 0.311 (95% CI 0.168-0.577),</s><s>P &lt; 0.001]; however, there was no significant interaction of the PIK3CA mutation status with type of anti-HER2 treatment (P = 0.189) (Figure <ref type="figure">1</ref>).</s><s>When taking treatment and HR status, a significant interaction of PIK3CA mutation with the HR status was confined to the cohort with trastuzumab and lapatinib (supplementary Figure <ref type="figure">S2</ref>, available at Annals of Oncology online).</s><s>After adjustment for age, tumour stage, nodal status, histological tumour type and grading, PIK3CA mutation status, HR status and treatment provided independent predictive information for achieving a pCR (supplementary Figure <ref type="figure">S3</ref>, available at Annals of Oncology online).</s><s>Treatment was only a significant independent predictor for pCR in the cohort with PIK3CA mutation survival</s></p><p><s>The median follow-up was 47 months: 40 months for Geparstudies (68 months for GeparQuattro, 54 months for GeparQuinto and 31 months for GeparSixto), 66 months for the NeoALTTO study and 46 months for the CHERLOB study.</s><s>There was no statistically significant difference in DFS (Figure <ref type="figure">2A</ref>) (HR mutant versus wild-type 1.07; 95% CI 0.76-1.50;</s><s>P = 0.691) and OS (supplementary Figure <ref type="figure">S5</ref>, available at Annals of Oncology online).</s><s>However, when taking into consideration HR status, there was a significant interaction between HR status and PIK3CA genotype.</s><s>The HR+ cohort showed a statistically significant worse DFS for the mutant cohort [Figure <ref type="figure">2C</ref>; HR 1.56 (95% CI 1.00-2.45),</s><s>P = 0.050], while there was a non-significant trend for a better DFS of the PIK3CA mutant /HR− group [Figure <ref type="figure">2B</ref>; HR 0.69 (95% CI 0.41-1.17),</s><s>P = 0.170] with a statistically significant interaction test (P = 0.021).</s></p><p><s>Since pCR is a known prognostic factor in HER2+ BC, combined survival analyses by pCR and PIK3CA and HR status were carried out (Figure <ref type="figure">2D</ref>).</s><s>In the pCR group, patients with a PIK3CA mutation tended to have better survival than those in the wild-type group irrespective of the HR status (log-rank test mutant versus wild-type P = 0.149).</s><s>Overall, there was no difference in DFS by mutation status in the non-pCR cohort (P = 0.797).</s><s>But HR non-pCR patients had a better survival with a mutation [HR mut versus wt HR1.53 (95% CI 0.96-2.43)</s><s>P = 0.073], whereas HR+ non-pCR patients had a better survival without a mutation [HR mut versus wt HR 0.68 (95%CI 0.39-1.17),</s><s>P = 0.164] (supplementary Figure <ref type="figure">S6A and B</ref>, available at Annals of Oncology online).</s></p><p><s>An explorative analysis whether a long-term treatment effect was detectable within the PIK3CA wild-type compared with the mutant cohort suggested, although not statistically significantly different, that, similar to the pCR results, dual anti-HER2 treatment improves DFS only in the wild-type cohort but not in the mutant cohort (log rank P interaction =0.392) and only in the HR population [HR 0.72 (95% CI 0.41-1.25),</s><s>P = 0.242] (Figure <ref type="figure">2E and F</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>discussion</head><p><s>We confirmed in almost 1000 HER2+ primary BC that tumours harbouring a PIK3CA mutation have a significantly lower pCR rate, especially in the group receiving T/L, although a trend within the monotherapy anti-HER2 treatment groups could be seen.</s><s>Combining both groups into a monotherapy anti-HER2 cohort (n = 566 patients) demonstrated a strong trend towards a lower pCR rate in the mutant compared with the wild-type cohort (15.9% versus 22.7%; P = 0.125), suggesting a small effect for PIK3CA mutations also there.</s><s>To show an absolute 7% pCR difference to be of statistical significance, a sample size of several thousands would have been needed.</s><s>However, in a recent smaller study, PTEN and the PIK3 downstream marker pEBP4 added information to the PIK3CA mutation status in a trastuzumab cohort <ref type="bibr" target="#b15">[16]</ref>.</s></p><p><s>Interestingly, PIK3CA status was observed to have a significant interaction with the HR status in the group treated with trastuzumab and lapatinib.</s></p><p><s>The role of PIK3CA in assessing the predictive effect in neoadjuvant therapy using the double blockade with trastuzumab plus pertuzumab has been less thoroughly investigated showing results comparable to ours <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>.</s></p><p><s>The Cleopatra study reported that patients with a PIK3CA mutation in their primary tumor had a significantly worse PFS, but mutation status did not predict greater benefit from double blockade <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s></p><p><s>In the DFS analysis, as in the pCR analysis, the HR status interacted with the PIK3CA mutation status.</s><s>HR-patients had a better DFS if their tumour harboured a PIK3CA mutation, whereas in HR+ patients, DFS was worse.</s></p><p><s>Despite a significant difference in the pCR rate, there was no difference in DFS and OS for patients with tumours harbouring a PIK3CA mutation, which is consistent with the data from the NSABP-B31 trial, even though the FinHER trial showed an improved survival within the first 3 years for the PIK3CA mutant cohort <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>The data for PIK3CA are not very conclusive regarding survival.</s><s>Numbers were either too small, or only a subcohort of the trial cohort was investigated or, as in the neoadjuvant setting, patients received longer anti-HER2 treatment in some trials or switched from lapatinib to trastuzumab after surgery <ref type="bibr" target="#b22">[23]</ref>.</s><s>Although exploratory, there seems to be benefit from the T/L combination in PIK3CA wt HR−/HER2+ patients.</s><s>The non-pCR group of that cohort had the worst prognosis from all subgroups.</s><s>A confirmation of these data in the much larger ALTTO trial would support the role of T/L in HR-/ HER2+/PIK3CA wt.</s><s>However in the HR+ group, the non-pCR PIK3CA mutant cohort had the worst prognosis, which warrants a chemofree quadruplet of dual blockade with anti-hormonetherapy and a more specific PI3K to be further investigated.</s></p><p><s>In the BOLERO 1 and 3 studies conducted in HER2+ metastatic BC, the effect of everolimus, an mTOR inhibitor acting downstream in the PI3Kinase pathway, was only detectable in the cohort harbouring a PIK3CA mutation <ref type="bibr" target="#b23">[24]</ref>.</s><s>Similar results were seen in Belle-2, when the pan PI3K inhibitor buparlisib in addition to fulvestrant in HER2−/HR+ metastatic BC improved PFS only in the group with a PIK3CA mutation detected in circulating tumour DNA <ref type="bibr" target="#b24">[25]</ref>.</s><s>The NeoPHOEBE study investigating buparlisib in HER2+ BC is too small and included only eight patients with a PIK3CA mutation, but demonstrated an increased response rate after 6 weeks by adding buparlisib to trastuzumab in the HR+ cohort <ref type="bibr" target="#b25">[26]</ref>.</s></p><p><s>This analysis has several strengths and limitations.</s><s>The integrated analysis using data from three different projects, including five different clinical trials, has the power to demonstrate a positive interaction of PIK3CA mutation status and the HR status regarding pCR when trastuzumab and lapatinib are used.</s><s>However, the power for the survival analysis is still limited.</s><s>To account for the fact that data from three different studies were combined, the multivariable models were adjusted for 'study'.</s><s>The different studies have used different sequencing approaches.</s><s>Sanger sequencing has been used as a standard method for a long time, while Sequenom and pyrosequencing technologies have been introduced more recently.</s><s>The backgrounds of the methods are different; in particular, the Sequenom technology  <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b27">28]</ref>.</s></p><p><s>In conclusion, PIK3CA mutation is associated with a lower pCR rate overall and particularly in HER2+ primary BC treated with trastuzumab and lapatinib in addition to chemotherapy.</s><s>This pooled analysis also demonstrated a significant interaction between HR and PIK3CA status and treatment for both pCR and DFS end points.</s><s>The data could be used to further subdivide the HER2+ population in order to improve outcome.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>acknowledgements</head><p><s>We thank all patients, clinicians and pathologists participating in the clinical studies and the biomaterial collection.</s><s>We thank the BIG headquarters and Ian Bradbury, Frontier Science for facilitating the data transfer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>funding</head><p><s>The individual clinical trials received funding from GSK/ Novartis, Roche, Sanofi-Aventis and TEVA.</s><s>The study was partially supported by a grant from the 7th EU frame work programme grant no 278659 'RESPONSIFY'.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>disclosure</head><p><s>RB is an employee of Genentech Inc.</s><s>South San Francisco; CD received honoraria from Roche and has ownership interest in Sividon Diagnostics; SL received research funding from Merck, Roche-Genentech, Pfizer and Novartis; MP received honoraria from Roche-Genentech and has a consulting role for Roche-Genentech; CS received expenses from Roche and has a consulting role for Oncodna, Vertex, Astellas and Cepheid; GM institution received research funding from Pfizer, Sanofi, Amgen, Roche, Novartis, Celgene, Teva, Boehringer, AstraZeneca and Myriad Genetics.</s><s>All remaining authors have declared no conflict of interest.</s><s>references</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>Pathological complete response rates according to PIK3CA mutation status overall, by HR status and anti-HER2 treatment.supplementaryTableS3andsupplementaryFigureS4available</s><s>at Annals of Oncology online).</s></p></div></figDesc><table><row><cell>Figure 1. Annals of Oncology</cell><cell>pCR</cell><cell>50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0%</cell><cell>n = 967 P &lt; 0.001 P interaction 1 = 0.036 P = 0.125 P &lt; 0.001 n = 424 n = 543 O v e r a l l H R -v e H R + v e T r a s t u z u m P = 0.343 P interaction 2 = 0.189 P = 0.389 n = 315 n = 251 a b L a p a t i n i b PIK3CA wt PIK3CA mutant 29.6% 16.2% 36.4% 27.2% 24.2% 7.6% 27.1% 20.3% 16.9% 11.3% original articles P &lt; 0.001 n = 401 T + L 39.1% 16.7%</cell></row></table><note><p><s>Volume 27 | No. 8 | August 2016 doi:10.1093/annonc/mdw197</s><s>|  (</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>detection of DNA fragments by MALDI-TOF mass spectrometry.</s><s>All three approaches, however, are focused on the analysis of defined mutational alterations.</s><s>This makes them particularly suitable for the analysis of PIK3CA, which has mutations located at defined hotspots.</s><s>Consequently, all three methods are well established and the PIK3CA mutation rates in the different studies are within the same range.</s><s>Comparative studies have been carried out for comparison of Sequenom analysis versus targeted next-generation sequencing (NGS) and Sanger sequencing versus targeted NGS with comparable results by both methods</s></p></div></figDesc><table><row><cell cols="8">original articles Annals of Oncology</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Annals of Oncology original articles</cell></row><row><cell>A</cell><cell cols="2">100%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>B</cell><cell cols="2">100%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>90%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">90%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>80%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">80%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Proportion disease-free</cell><cell></cell><cell>30% 40% 50% 60% 70%</cell><cell></cell><cell></cell><cell></cell><cell cols="6">+ Censored wt 145/755 events HR mut to wt = 1.07, 95% CI (0.76, 1.50) Log rank P = 0.6906</cell><cell>Proportion disease-free</cell><cell cols="2">30% 40% 50% 60% 70%</cell><cell></cell><cell></cell><cell cols="4">+ Censored wt 81/330 events HR mut to wt = 0.69, 95% CI (0.41, 1.17) Log rank P = 0.1698</cell></row><row><cell></cell><cell></cell><cell>20%</cell><cell></cell><cell></cell><cell></cell><cell cols="3">mut 44/210 events</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">20%</cell><cell></cell><cell></cell><cell cols="4">mut 17/92 events</cell></row><row><cell></cell><cell></cell><cell>10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell><cell>48</cell><cell>60</cell><cell>72</cell><cell>84</cell><cell>96</cell><cell></cell><cell></cell><cell></cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell><cell>48</cell><cell>60</cell><cell>72</cell><cell>84</cell><cell>96</cell></row><row><cell>wt</cell><cell></cell><cell cols="6">755 691 598 462 282</cell><cell>111</cell><cell>36</cell><cell>10</cell><cell>1</cell><cell>wt</cell><cell></cell><cell cols="6">330 301 258 199 120</cell><cell>44</cell><cell>12</cell><cell>4</cell><cell>0</cell></row><row><cell cols="2">mut</cell><cell cols="5">210 193 166 128</cell><cell>91</cell><cell>30</cell><cell>11</cell><cell>2</cell><cell>0</cell><cell>mut</cell><cell></cell><cell></cell><cell>92</cell><cell>85</cell><cell>73</cell><cell>60</cell><cell>47</cell><cell>15</cell><cell>6</cell><cell>1</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">DFS, months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">DFS, months</cell></row><row><cell>C</cell><cell cols="2">100%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>D</cell><cell cols="2">100%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>90%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">90%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Proportion disease-free</cell><cell></cell><cell>20% 30% 40% 50% 60% 70% 80%</cell><cell></cell><cell></cell><cell></cell><cell cols="6">+ Censored mut 27/118 events wt 64/425 events HR mut to wt = 1.56, 95% CI (1.00, 2.45) Log rank P = 0.0502</cell><cell>Proportion disease-free</cell><cell cols="2">20% 30% 40% 50% 60% 70% 80%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">+ Censored mut pCR 1/34 events mut no pCR 43/176 events wt pCR 25/223 events wt no pCR 120/532 events</cell></row><row><cell></cell><cell></cell><cell>10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell><cell>48</cell><cell>60</cell><cell>72</cell><cell>84</cell><cell>96</cell><cell></cell><cell></cell><cell></cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell><cell>48</cell><cell>60</cell><cell>72</cell><cell>84</cell><cell>96</cell></row><row><cell cols="2">wt mut</cell><cell cols="6">425 390 340 263 162 118 108 93 68 44</cell><cell>67 15</cell><cell>24 5</cell><cell>6 1</cell><cell>1 0</cell><cell cols="2">wt no pCR wt pCR</cell><cell cols="2">532 223</cell><cell>476 215</cell><cell>401 197</cell><cell>313 149</cell><cell>195 87</cell><cell>71 40</cell><cell>23 13</cell><cell>5 5</cell><cell>1 0</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">mut no pCR</cell><cell cols="2">176</cell><cell>162</cell><cell>137</cell><cell>106</cell><cell>75</cell><cell>19</cell><cell>7</cell><cell>1</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">mut pCR</cell><cell></cell><cell>34</cell><cell>31</cell><cell>29</cell><cell>22</cell><cell>16</cell><cell>11</cell><cell>4</cell><cell>1</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">DFS, months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">DFS, months</cell></row><row><cell>E</cell><cell cols="2">100%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>F</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>90%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">90%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>80%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">80%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Proportion disease-free</cell><cell></cell><cell>30% 40% 50% 60% 70%</cell><cell></cell><cell></cell><cell cols="3">+ Censored TL 42/315 events L 46/189 events T 57/251 events Log rank P = 0.1856</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Proportion disease-free</cell><cell cols="2">30% 40% 50% 60% 70%</cell><cell></cell><cell></cell><cell cols="3">+ Censored TL 17/84 events L 13/62 events T 14/64 events Log rank P = 0.8405</cell></row><row><cell></cell><cell></cell><cell>20%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">20%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0%</cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell><cell>48</cell><cell>60</cell><cell>72</cell><cell>84</cell><cell>96</cell><cell></cell><cell cols="2">0%</cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell><cell>48</cell><cell>60</cell><cell>72</cell><cell>84</cell><cell>96</cell></row><row><cell>T</cell><cell></cell><cell cols="6">251 229 213 190 142</cell><cell>71</cell><cell>20</cell><cell>4</cell><cell>1</cell><cell>T</cell><cell></cell><cell></cell><cell>64</cell><cell>59</cell><cell>52</cell><cell>47</cell><cell>39</cell><cell>14</cell><cell>6</cell><cell>1</cell><cell>0</cell></row><row><cell>L</cell><cell></cell><cell cols="5">189 172 151 130</cell><cell>84</cell><cell>26</cell><cell>9</cell><cell>3</cell><cell>0</cell><cell>L</cell><cell></cell><cell></cell><cell>62</cell><cell>54</cell><cell>51</cell><cell>43</cell><cell>33</cell><cell>11</cell><cell>1</cell><cell>0</cell><cell>0</cell></row><row><cell>TL</cell><cell></cell><cell cols="5">315 290 234 142</cell><cell>56</cell><cell>14</cell><cell>7</cell><cell>3</cell><cell>0</cell><cell cols="2">TL</cell><cell></cell><cell>84</cell><cell>80</cell><cell>63</cell><cell>38</cell><cell>19</cell><cell>5</cell><cell>4</cell><cell>1</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">DFS, months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">DFS, months</cell></row><row><cell cols="4"> | Loibl et al.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Volume 27 | No. 8 | August 2016</cell></row></table><note><p><s>100% Figure 2. Survival curves: (A) disease-free survival by PIK3CA mutation status; (B and C) disease-free survival by PIK3CA mutation status in hormone receptor negative (B) and positive (C) tumours (interaction of HR status and PIK3CA p = 0.021).</s><s>(D) Disease-free survival according to pathological complete response and PIK3CA mutation status.</s><s>Disease-free survival by anti-HER2 treatment (trastuzumab, lapatinib and trastuzumab plus lapatinib) in patients with PIK3CA wild-type (E) and PIK3CA mutant (F) tumours.</s><s>Volume 27 | No. 8 | August 2016 doi:10.1093/annonc/mdw197</s><s>|  uses</s></p></note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Obstet Gynecol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="85" to="91" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schneeweiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hickish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2278" to="2284" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The PIK3CA gene is mutated with high frequency in human breast cancers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Bachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Argani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Samuels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Biol Ther</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="772" to="775" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">PIK3CA mutations are associated with lower rates of pathological complete response ( pCR) to anti-HER2 therapy in primary HER2-overexpressing breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneeweiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3212" to="3220" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Majewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nuciforo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mittempergher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1334" to="1339" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Guarneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Dieci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frassoldati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1001" to="1010" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Dual blockade with afatinib and trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy-DAFNE (GBG-70)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hanusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneeweiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2924" to="2931" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Untch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rezai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2024" to="2031" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Untch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bischoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="135" to="144" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial</title>
		<author>
			<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneeweiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="747" to="756" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Lapatinib with trastuzumab forHER2-positive early breast cancer (NeoALTTO): a randomised, open label, multicentre, phase 3 trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bradbury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Eidtmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="633" to="640" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Guarneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frassoldati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bottini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1989" to="1995" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Reporting recommendations for tumor marker prognostic studies (REMARK)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="1180" to="1184" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Guarneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Generali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frassoldati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1050" to="1057" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Analysis of PIK3CA mutations in breast cancer subtypes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Arsenic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Budczies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Mol Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="50" to="56" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">PTEN expression and p4EBP1 immunoreactive score as predictor for pCR in HER2+ breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Darb-Esfahani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huober</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients ( pts) with HER2-positive breast cancer (BC)</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bianchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kiermaier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="S5" to="S6" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab-and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schneeweiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">R73</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cortés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="109" to="119" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Biomarker analysis in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cortés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Im</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3753" to="3761" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Pogue-Geile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Jeong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1340" to="1347" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Michiels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lambrechts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="960" to="967" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemotherapy with trastuzumab or lapatinib: survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Untch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gerber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page">S268</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3</title>
		<author>
			<persName><forename type="first">D</forename><surname>Slamon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hurvitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">2015</biblScope>
			<biblScope unit="page">512</biblScope>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): first results from the randomized, Phase III BELLE-2 trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-A</forename><surname>Im</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Iwata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Abstract S6-01</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer-NeoPHOEBE</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De La Pena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nekljudova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="page" from="P1" to="14" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ibarrola-Villava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fleitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Llorca-Cardeñosa</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.8002</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Arsenic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Treue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lehmann</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdw203</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Oncology</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1525" to="1531" />
			<date type="published" when="2015">2015. 2016. May 2016</date>
		</imprint>
	</monogr>
	<note>BMC Clin Pathol. Published online 13</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
